Intellia Therapeutics

NTLA

Market cap $1.53B

NTLA Hedge Fund Activity: Q1 2026 in Review

302 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2026, worth a combined $1.42B — up 51% from $938M a quarter earlier.

Buyers outnumbered sellers: 63 funds opened new NTLA positions and 46 closed out — a net gain of 17 holders — while 127 added to existing stakes and 63 trimmed.

The largest buyer was Two Sigma Investments, adding an estimated $25.6M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $15M sold.

• 302 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2026, up from 291 in Q4 2025.
• Funds reported $1.42B of Intellia Therapeutics stock for Q1 2026, up 51% quarter-over-quarter.
• 63 funds opened new Intellia Therapeutics positions in Q1 2026 and 46 closed out, a net change of +17 holders.
• The largest Intellia Therapeutics buyer in Q1 2026 was Two Sigma Investments, an estimated $25.6M added.
• The largest Intellia Therapeutics seller in Q1 2026 was Renaissance Technologies, an estimated $15M sold.

Based on aggregated 13F filings for Q1 2026.